my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
01-24-2011: Evotec AG announced that it has entered into a collaboration with Takeda Cambridge Limited, to identify small molecule modulators against GPCR and Protease targets involved in various CNS and Metabolic diseases.
Evotec will apply its state-of-the-art Screening Platform and proprietary GPCR modeling software to identify and validate novel modulators against various targets selected by Takeda Cambridge.
Dr Mario Polywka, Chief Operating Officer at Evotec stated: "We are proud to be selected by Takeda Cambridge to collaborate on this important project. We have invested significantly in our world leading, hit-identification platform and this alliance further validates the strength of this platform and Evotec's ability to bring value to its partner's drug discovery efforts. We look forward to working with Takeda Cambridge."
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
4-Antibody AG and Evotec AG Form Strategic Collaboration
4-Antibody AG and Evotec AG announced the signing of a strategic collaboration agreement under which Evotec will offer a fully integrated antibody discovery and development service. Evotec’s novel and unique high throughput and high content screening approach coupled with 4-Antibody’s high ... more
Evotec Achieves Two Milestones in Fragment-based Drug Discovery Alliance with Shionogi
Evotec AG announced the achievement of specific success criteria in a multiple target drug discovery collaboration with Shionogi & Co Ltd. and the receipt of two milestone payments. Evotec and Shionogi will continue to collaborate to progress the fragments through the drug discovery process ... more
Evotec and APEIRON Biologics start next project on the Cbl-b target
Evotec AG and Apeiron Biologics AG announced that they have entered into a further discovery project on the Cbl-b target, an excellent target for anti-tumor immune therapy.Cbl-b plays a role in both the adaptive and the innate immune system and its manipulation therefore can effectively enh ... more
Evotec is a leading drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches. The Company operates worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target ... more
Evotec is a leader in the discovery and development of novel small molecule drugs. The Company has established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System (CNS) related diseases where it is b ... more
Evotec to Collaborate with Takeda Cambridge for Multi-target Hit Identification
Evotec AG announced that it has entered into a collaboration with Takeda Cambridge Limited, to identify small molecule modulators against GPCR and Protease targets involved in various CNS and Metabolic diseases.Evotec will apply its state-of-the-art Screening Platform and proprietary GPCR ... more
Takeda Pharmaceutical Company Limited announced that an additional indication for “NESINA®” (generic name: Alogliptin), combination therapy with thiazolidinediones for type 2 diabetes, was approved by the Japanese Ministry of Health, Labour and Welfare. NESINA, a dipeptidyl peptidase-IV ( ... more
Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin for Treatment of Type 2 Diabetes
Takeda Pharmaceutical Company Limited and Takeda Global Research & Development Center, Inc., a wholly owned United States subsidiary, jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascu ... more
Takeda San Diego (TSD) is Takeda's global center for excellence in structure-based drug discovery. TSD integrates cutting-edge protein crystallography and drug discovery technologies to efficiently generate Investigational New Drug (IND) candidates for the treatment of metabolic diseases an ... more
About CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2012 CHEMIE.DE Information Service GmbH, All rights reserved
